SV

Street Verdict

Analyst Scorecard

A record of what Axis Securities Analysis said publicly, with the source. Not advice.

“Axis Securities has an 'Overweight' call on Aurobindo Pharma, setting a target price of Rs 1,500 against the current market price of Rs 1173.85. The company's future valuations depend on the return on invested capital from its Rs 7,000 crore capex in Biosimilars and Pen-G. Risks include OAI for injectable segments impacting new launches and price erosion in the injectable portfolio affecting gross margins in upcoming quarters.”

Axis Securities Analysis’s track record (trackable calls only): 155 graded calls · 95% CI 34–49%

Aurobindo Pharma LtdBullishCalled 14 Jan 2025Graded 14 Jan 2026
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹1,500, as stated.

Window: 12 months, the default when no time frame is stated.

Neither the target ₹1,500 was reached on a close by the end of the window. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹1147.55 on 2025-01-15 (next trading session's close); neither target nor stop reached by window end 2026-01-14. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

Tracking Aurobindo Pharma Ltd since this call

1-year tracking window
Read the original articleSee Axis Securities Analysis’s full track record